Grant Number:	5U2CCA252973-05 Interpret this number
Primary Investigator:	Willman, Cheryl
Organization:	University Of New Mexico Health Scis Ctr
Project Title:	Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
Fiscal Year:	2025

While sovereign American Indian and Alaskan Native (AI/AN) tribes and communities across the United States have distinct languages and cultures, there is one unfortunate characteristic they share: extremely poor cancer health outcomes. Compounded by lower rates of cancer screening and more limited access to healthcare, AI/AN are more often diagnosed at later stages of disease and have the poorest outcomes for all types of cancer when compared to any other population in the United States. While the cause of these poor cancer health outcomes is likely multifactorial, a potential and largely unexplored factor is variation in the molecular genetic profiles of cancers arising in AI/AN. AI/AN populations were strikingly understudied in The NIH Cancer Genome Atlas Project (TCGA), accounting for < 0.5% of the cancer patients studied from across the nation. Of the nearly 11,000 patients sequenced in TCGA, only 27 (0.25%) were identified as AI/AN. It is our hypothesis that through appropriate, respectful AI/AN participant and community engagement and comprehensive genomic sequencing, we will discover novel germline and somatic tumor mutations, differences in the spectrum and/or frequency of cancer-promoting mutations, and genome-wide mutational signatures reflective of distinct exposures. It is our goal to translate these discoveries to improved cancer screening, precision prevention, and therapeutic intervention for AI participants and their communities. These studies will contribute new knowledge that benefits all U.S. populations. In this PE-CGS Center, while all cancers are under study, we are focusing on the molecular characterization of cancers that occur with increased frequency or those which are associated with particularly poor outcomes in AI communities in the American Southwest including: gastrointestinal and hepatobiliary cancers (stomach, colorectal, pancreatic, liver, biliary tract); genitourinary cancers (kidney, prostate); and other hormone-dependent cancers (breast, ovarian cancers). Our Specific Aims are to develop respectful and trusted means to: 1) Engage AI participants (cancer patients, survivors), Tribal Advisory and Governance Committees, and communities in participatory research studies of the molecular characterization of cancer, particularly focusing on cancers that display striking differences in incidence and outcome in Tribal Nations in the Southwest; 2) Discover novel somatic and germline mutations and/or differences in the spectrum and frequency of cancer-promoting mutations, and genome-wide mutational signatures reflective of specific exposures in AI participants, relative to other U.S. populations; 3) Disseminate clinical grade sequencing results and knowledge gained directly to cancer patient participants and their healthcare providers for their beneficence, supported with genetic counseling and navigation to treatment; and 4) Share anonymized, deidentified data and knowledge gained to Tribal participants, Advisory Committees, leaders, and communities using respectful means of engagement and communication, and also with the broader scientific community through the NCI Genome Data Commons and publication of scientific results in accordance with NIH Data Sharing Policies and Tribal Data Use Agreements.




Optimizing participant and community engagement in cancer genomic sequencing research.
Authors: Crossnohere N.L. , Schuster A.L.R. , Blair C.K. , Bland H. , Carpten J.D. , Claus E.B. , Colditz G.A. , Diehl D. , Ding L. , Drake B.F. , et al. .
Source: Genetics In Medicine : Official Journal Of The American College Of Medical Genetics, 2025 Sep; 27(9), p. 101483.
EPub date: 2025-06-11 00:00:00.0.
PMID: 40517303
Related Citations

The human pangenome reference anticipates equitable and fundamental genomic insights.
Authors: Frazer K.A. , Schork N.J. .
Source: Cell Genomics, 2023-07-12 00:00:00.0; 3(7), p. 100360.
EPub date: 2023-07-12 00:00:00.0.
PMID: 37492100
Related Citations

Priorities to promote participant engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network.
Authors: Schuster A.L.R. , Crossnohere N.L. , Bachini M. , Blair C.K. , Carpten J.D. , Claus E.B. , Colditz G.A. , Ding L. , Drake B.F. , Fields R.C. , et al. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2023-02-15 00:00:00.0; , .
EPub date: 2023-02-15 00:00:00.0.
PMID: 36791345
Related Citations

A time-series analysis of blood-based biomarkers within a 25-year longitudinal dolphin cohort.
Authors: Rangan A.V. , McGrouther C.C. , Bhadra N. , Venn-Watson S. , Jensen E.D. , Schork N.J. .
Source: Plos Computational Biology, 2023 Feb; 19(2), p. e1010890.
EPub date: 2023-02-21 00:00:00.0.
PMID: 36802395
Related Citations

Interrogating the Human Diplome: Computational Methods, Emerging Applications, and Challenges.
Authors: Chan A.P. , Choi Y. , Rangan A. , Zhang G. , Podder A. , Berens M. , Sharma S. , Pirrotte P. , Byron S. , Duggan D. , et al. .
Source: Methods In Molecular Biology (clifton, N.j.), 2023; 2590, p. 1-30.
PMID: 36335489
Related Citations

Exploring human biology with N-of-1 clinical trials.
Authors: Schork N.J. , Beaulieu-Jones B. , Liang W.S. , Smalley S. , Goetz L.H. .
Source: Cambridge Prisms. Precision Medicine, 2023; 1, .
EPub date: 2023-01-10 00:00:00.0.
PMID: 37255593
Related Citations

The inflammatory response of human pancreatic cancer samples compared to normal controls.
Authors: Brayer K.J. , Hanson J.A. , Cingam S. , Martinez C. , Ness S.A. , Rabinowitz I. .
Source: Plos One, 2023; 18(11), p. e0284232.
EPub date: 2023-11-01 00:00:00.0.
PMID: 37910468
Related Citations

A Framework for Promoting Diversity, Equity, and Inclusion in Genetics and Genomics Research.
Authors: Rebbeck T.R. , Bridges J.F.P. , Mack J.W. , Gray S.W. , Trent J.M. , George S. , Crossnohere N.L. , Paskett E.D. , Painter C.A. , Wagle N. , et al. .
Source: Jama Health Forum, 2022 Apr; 3(4), .
EPub date: 2022-04-15 00:00:00.0.
PMID: 35755401
Related Citations

Does Modulation of an Epigenetic Clock Define a Geroprotector?
Authors: Schork N.J. , Beaulieu-Jones B. , Liang W. , Smalley S. , Goetz L.H. .
Source: Advances In Geriatric Medicine And Research, 2022; 4(1), .
EPub date: 2022-03-29 00:00:00.0.
PMID: 35466328
Related Citations